<DOC>
	<DOC>NCT02900027</DOC>
	<brief_summary>The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS APOC-III-LRx given to healthy volunteer subjects.</brief_summary>
	<brief_title>Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides</brief_title>
	<detailed_description />
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Must have given written informed consent and be able to comply with all study requirements Healthy males or females aged 1865 inclusive Females must be nonpregnant and nonlactating, and either surgically sterile or post menopausal Males must be surgically sterile, abstinent or using an acceptable contraceptive method BMI &lt; 35.0 kg/m2 Subjects must have Fasting TG ≥ 90 mg/dL or ≥ 200 mg/dL depending on Cohort assignment Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B Treatment with another Study Drug, biological agent, or device within onemonth of screening Regular excessive use of alcohol within 6 months of Screening Use of concomitant drugs unless authorized by the Sponsor Medical Monitor Smoking &gt; 10 cigarettes a day Considered unsuitable for inclusion by the Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>